BACE1 and Alzheimer disease: Subdividing the patient group into pre-AD and full-AD according to the disease progression evaluated by MMSE, another study found that plasma levels of BACE1-AS were low in the pre-AD subgroup compared with full-AD subjects and healthy controls.